Video

Gil Melmed, MD: Biologics for Inflammatory Bowel Disease

Author(s):

On June 3, 2021, Gil Melmed, MD, led an HCPLive State of the Science expert webinar on the current and future state of inflammatory bowel disease (IBD).

Melmed, Director of Inflammatory Bowel Disease Clinical Research at Cedars-Sinai, was joined by his Cedars-Sinai colleagues Christina Ha, MD, Dermot McGovern, MD, PhD, and Gaurav Syal, MD for a 90-minute program on the following topics:

  • IBD and COVID-19: What have we learned?
  • Biologics for IBD – when, which one, and in whom?
  • Algorithms of Care for IBD
  • Emerging Therapies – the future is bright!

In the clip above, Melmed joins HCPLive for a recap interview on the subjects of the program, highlighting current biologic therapy options for IBD, and what future clinical research should entail.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
© 2024 MJH Life Sciences

All rights reserved.